3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 3
7
Phase 1
6
Phase 1/2
4
Phase NA
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Squamous Cell Carcinoma of Head and Neck
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Carcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
4
Cisplatin
4
Capecitabine
4
Oxaliplatin
3
Leucovorin
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
titanium silicide
1
tegafur-gimeracil-oteracil
1
surufatinib
1
pembrolizumab
1
mitazalimab
1
durvalumab
1
cediranib
1
anlotinib
1
Taxes
1
S 1 (combination)
1
Paclitaxel
1
Folfox protocol
1
Control Groups
1
ARRY-334543
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Biliary Tract Neoplasms
×
durvalumab
×
Clear all
NCT06214572
2025-04-11
RUGB
Tata Memorial Centre
Phase 2/3
Recruiting
249 enrolled